Trimethylamine-producing gut microbial metabolic pathways (TMA/TMAO pathway)

The trimethylamine (TMA)-producing gut microbial metabolic pathway is a metaorganismal process where anaerobic gut bacteria convert dietary nutrients—primarily choline, L-carnitine, and betaine—into the volatile compound TMA (1.1.1, 1.3.1). Once produced in the gut, TMA is absorbed into the portal circulation and transported to the liver, where it is oxidized by host flavin-containing monooxygenases (primarily FMO3) to form trimethylamine N-oxide (TMAO) (1.1.5, 1.2.1). Elevated systemic levels of TMAO have been strongly linked to the pathogenesis of various cardiometabolic disorders, including atherosclerosis, heart failure, and chronic kidney disease, by promoting vascular inflammation, foam cell formation, and platelet hyperreactivity (1.2.3, 1.2.5). This pathway has emerged as a significant therapeutic target, with research focusing on small-molecule inhibitors that target specific microbial enzymes like choline-TMA lyase (CutC/D) and carnitine monooxygenase (CntA/B) (1.3.2, 1.4.4). Unlike traditional antibiotics, these inhibitors, such as 3,3-dimethyl-1-butanol (DMB) and iodomethylcholine (IMC), are designed to be non-lethal to the bacteria, thereby reducing TMA production without exerting strong selective pressure that could lead to antimicrobial resistance or major dysbiosis (1.4.1, 1.4.5). Monitoring plasma TMAO levels serves as a key biomarker for assessing the efficacy of these interventions and the associated cardiovascular risk (1.2.2, 1.2.4).

Other names

Gut microbial TMA/TMAO pathwayCholine-TMA lyase pathwayCarnitine-TMA lyase pathwayMicrobial TMA-producing enzymesCutC/D pathwayCntA/B pathway

Non-lethal inhibition of microbial trimethylamine (TMA) lyases, such as choline-TMA lyase (CutC/D) and carnitine monooxygenase (CntA/B), to prevent the conversion of dietary precursors into TMA without killing the bacteria (1.4.1, 1.4.5).